Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what plans he has for the use of the breast cancer treatment capivasertib in the NHS.

Capivasertib is not yet licensed for the treatment of breast cancer in the United Kingdom. While the Medicines and Healthcare products Regulatory Agency (MHRA) assesses any submitted applications for new healthcare products and is willing to facilitate the appropriate regulatory processes, the agency cannot actively seek these applications. The MHRA is aware of clinical trials for capivasertib to treat multiple subtypes of breast cancer, including triple negative breast cancer, however we are not able to comment on any company submission or licencing status related to this at this point in time.

Capivasertib would be considered for appraisal by the National Institute for Health and Care Excellence (NICE) if it were to receive a licence from the MHRA. The NHS in England is legally required to fund drugs recommended by NICE, usually within three months of final guidance.